Stockreport

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 part [Read more]